Mechanisms of tubulointerstitial fibrosis.
By M. Zeisberg, Eric G. Neilson. Journal of the American Society of Nephrology, 2010
949 citations recorded by the source corpus.
The pathologic paradigm for renal progression is advancing tubulointerstitial fibrosis. Whereas mechanisms underlying fibrogenesis have grown in scope and understanding in recent decades, effective human treatment to directly halt or even reverse fibrosis remains elusive. Here, we examine key features mediating the molecular and cellular basis of tubulointerstitial fibrosis and highlight new insights that may lead to novel therapies. How to prevent chronic kidney disease from progressing to renal failure awaits even deeper biochemical understanding.
Subfields: Hepatology, Nephrology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/0738214147f482cd0ab1b0385ac49d354035248e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Nephrology
In Pharmacology
Citations in the corpus
- Cellular and molecular mechanisms of fibrosis (2008, background): “Therefore, therapies that target the renin–angiotensin–aldosterone system or TGFβ1 pathways might provide effective strategies to slow the progression of fibrosis in hypertensive heart disease, progressive renal disease and hepatic fibrosis [144,147,148].”